Why this trial matters : First ADC to move into the 1L HER2+ metastatic setting Breaks a decade-long treatment paradigm in first-line breast cancer care Confirms ADCs as frontline platforms, not just late-line salvage therapies Roche Giredestrant Delivers the First Phase III Win for an Oral SERD in Early Breast Cancer Roches oral SERD giredestrant reduced the risk of invasive disease recurrence versus standard endocrine therapy in the Phase III lidERA trial in ER-positive, HER2-negative early breast cancer, marking the first major advance in adjuvant endocrine therapy in decades
It delivers meaningful, long-lasting results with no surgeryand benefits that continue to improve over time
Without glutathione, the antioxidant capacity is significantly reduced
Low levels of B12 impair DNA synthesis, which interferes with the activation of folate and, as a result, reduces the production of normal red blood cells and subsequently impairs oxygen delivery
For those affected, this can mean a constant urge to urinate, accompanied by a burning sensation and pain that doesnt subside
